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Abstract
CDKN1C (also known as P57kip2) is a cyclin-dependent kinase inhibitor that functions as a negative regulator of cell
proliferation through G1 phase cell cycle arrest. Recently, our group described gain-of-function mutations in the
PCNA-binding site of CDKN1C that result in an undergrowth syndrome called IMAGe Syndrome (Intrauterine Growth
Restriction, Metaphyseal dysplasia, Adrenal hypoplasia, and Genital anomalies), with life-threatening consequences.
Loss-of-function mutations in CDKN1C have been identified in 5-10% of individuals with Beckwith-Wiedemann
syndrome (BWS), an overgrowth disorder with features that are the opposite of IMAGe syndrome. Here, we investigate
the effects of IMAGe-associated mutations on protein stability, cell cycle progression and cell proliferation. Mutations in
the PCNA-binding site of CDKN1C significantly increase CDKN1C protein stability and prevent cell cycle progression into
the S phase. Overexpression of either wild-type or BWS-mutant CDKN1C inhibited cell proliferation. However, the
IMAGe-mutant CDKN1C protein decreased cell growth significantly more than both the wild-type or BWS protein.
These findings bring new insights into the molecular events underlying IMAGe syndrome.
Keywords: Cell cycle, CDK-inhibitor, IMAGe syndrome, Cyclin, Beckwith Wiedemann syndrome, Intrauterine growth
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Findings
CDKN1C (also known as p57kip2) is a cyclin-dependent
kinase inhibitor sharing CDKN1B (p27Kip1) and
CDKN1A (p21WAF1/Cip1) homology that has a key role
in inhibiting cell cycle progression by blocking the cells
in G1 phase [1]. It is located on chromosome 11p15.5
and is part of a cluster of imprinted genes. The
CDKN1C protein has 316 amino acids (AA) and consists
of three structurally distinct domains: the N-terminal
domain (AA 1 – 110), necessary for CDK inhibition; a
central proline-alanine series of repeats (PAPA-repeats,
AA 156 – 213), and a highly conserved C-terminal region
(QT domain, AA 214 – 316), where the PCNA binding
site is located [2,3]. In nearly all tissues, CDKN1C is
expressed from the maternal allele while the paternal allele
is silenced [1,2].
Recently, our group identified missense mutations in
the PCNA-binding domain of CDKN1C in families with
IMAGe syndrome (MIM# 614732), characterized by
Intrauterine growth retardation, Metaphyseal dysplasia,
Adrenal hypoplasia and Genital anomalies.[4] Interest-
ingly, CDKN1C mutations have previously been identi-
fied in Beckwith-Wiedemann Syndrome (BWS; MIM#
130650) and are distributed throughout entire length of
the coding sequence of the gene. These BWS-associated
mutations are either missense mutations that disrupt the
cyclin-dependent kinase binding domain, or nonsense
mutations, both of which result in protein loss-of-
function [3,4]. CDKN1C mutations have been found in
5–10% of sporadic BWS cases and in approximately 40%
of cases with a family history [3].
We hypothesize that IMAGe syndrome mutations re-
sult in loss of PCNA-binding and a gain-of-function of
CDKN1C. Previous studies demonstrated that IMAGe-
mutant CDKN1C and BWS-mutant CDKN1C have
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differential effects on cell cycle progression, develop-
mental processes, suggesting that domain-specific muta-
tions act through distinct mechanisms [4]. Early studies
have also shown that targeted eye expression of IMAGe-
mutant CDKN1C mutations in Drosophila cause severe
growth defects compared to wild type CDKN1C. Fur-
thermore, an in vitro assay showed that IMAGe-mutant
CDKN1C protein presents alteration in its ubiquitina-
tion pattern [4]. Here, we aim to investigate the molecu-
lar mechanisms underlying the IMAGe mutations. To
address this, we performed functional studies with wild-
type, IMAGe-mutant and BWS-mutant CDKN1C pro-
teins. IMAGe-mutant protein consists of a mutation in the
PCNA binding domain and an intact cyclin-dependent kin-
ase binding domain whereas CDKN1C BWS-mutant pro-
tein contains a mutation in the cyclin-dependent kinase
binding domain and a wild-type PCNA binding site. Our
results showed that missense mutations in the PCNA-
binding site of CDKN1C lead to protein stabilization, im-
paired entry into S-phase, culminating in decreased cell
proliferation. Moreover, IMAGe-mutants displayed dif-
ferent effects relative to BWS-mutants, suggesting that
domain-specific mutations have differential effects on cell-
cycle progression and cell proliferation.
Loss of PCNA binding in IMAGe-mutant CDKN1C results in
increased protein stability and loss of normal oscillation
of CDKN1C protein during cell cycle progression
Mutations in the PCNA binding domain of the related
protein CDKN1A, which shares sequence homology with
CDKN1C, prevents its degradation [5]. Therefore, we de-
cided to investigate whether the loss of direct binding of
PCNA alters the degradation of CDKN1C. To address
this, we transiently overexpressed wild-type or IMAGe-
mutant (p.K278E and p.F276V) CDKN1C into HEK293T
cells and examined the protein degradation rate of
CDKN1C in the presence of the de novo protein synthesis
inhibitor cycloheximide (100 μg/mL). pcDNA3.1-FLAG-
CDKN1C constructs used here were described previously
[4]. The following antibodies were used in our western
blot experiments: anti-CDKN1C (Santa Cruz Biotechnol-
ogy, sc-1040), anti-Cyclin A (Santa Cruz Biotechnology,
sc-271682) and anti-B-actin (Abcam, mAbcam 8226). The
secondary antibodies used were goat anti-mouse HRP
(Bio-rad, 170–5047) and goat anti-rabbit HRP (Santa Cruz
Biotechnology, sc-2030). IMAGe-mutant CDKN1C (p.
K278E and p.276 V) led to increased stabilization of
CDKN1C compared to wild-type CDKN1C (Figure 1).
This is in accordance with recently published results,
where IMAGE-associated proteins also demonstrated in-
creased stability compared to wild-type [6,7].
Regulation of protein turnover is required for normal
progression through the cell cycle. Since loss of PCNA-
binding led to increased stabilization of CDKN1C, we
hypothesized that the turnover of CDKN1C during the
cell cycle progression might be altered. To investigate this,
we developed a protocol where HEK293T cells progress
into S-phase in the presence of different CDKN1C proteins
(wild-type, IMAGe-mutant (p.K278E) and BWS-mutant
(p.L42P)). The BWS-mutant has a mutation in the cyclin
dependent kinase (CDK) inhibitory domain, but expresses a
normal PCNA binding domain, while the IMAGe-mutant
p.K278E has been previously shown to have loss of PCNA
binding [4]. Cultures of HEK293T cells were synchronized
using an initial thymidine block (2 mM) at G1/S border
phase and upon release of the thymidine block transfected
with their respective plasmids. Cells were resynchronized
with thymidine (Figure 2A) and after a second wash were
harvested at various time points and processed for western
blot and cell cycle analysis, as described [4].
Western blot analysis showed that in cells transfected
with either the wild-type or BWS-mutant CDKN1C, the
CDKN1C protein levels oscillated, peaking at 3 and
15 hours after the release. On the other hand, protein
levels of IMAGe-mutant CDKN1C remained at cons-
tant levels throughout the entire 24-hour time course
(Figure 2B). These results show that IMAGe mutations
result in increased stability and a loss of normal oscilla-
tion of CDKN1C protein levels. This is consistent with
previous results showing loss of ubiquitination [4] and
indicates that normal progression through the cell cycle
is disturbed when the IMAGe-mutant is expressed.
IMAGe-mutant CDKN1C impairs entry into S phase in
synchronized cells
In order to understand the effects of CDKN1C on cell cycle
progression, we examined cell cycle phase distribution of
the cells from the experiment described in Figure 2A. Upon
Figure 1 IMAGe-mutant CDKN1C stabilizes CDKN1C protein. Cells were transiently transfected with plasmids expressing CDKN1C wild-type or
IMAGE-mutants (p.K278E and p.F276V). After addition of cycloheximide (CHX) at 100 μg/mL to the culture medium, cells were harvested at various
times and processed by Western blot analysis of CDKN1C protein.
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release at G1/S phase, cells transfected with empty plasmid
or BWS-mutant CDKN1C progressed synchronously
through the entire cell cycle (Figure 2C) whereas a larger
proportion of wild-type and IMAGe-mutant CDKN1C
transfected cells were unable to progress through the cell
cycle and remained in G1 phase after T0 (Figure 2C). These
data indicate that IMAGe-mutant CDKN1C protein pre-
vents G1/S phase transition as CDKN1C wild-type protein.
To further investigate this, we examined cell cycle phase
distribution of the cells at time T0. The percentage of the
cells in the G1 phase was increased by the transfection of
wild-type CDKN1C compared with empty plasmid and
BWS-mutant (32.31%, 14.88% and 19.85% respectively).
However, cells transfected with IMAGe-mutant CDKN1C
had the highest percentage of cells in the G1 phase
(36.94%) and the lowest proportion of cells in the S-phase
(40.06%) (Figure 3A).
Given the differences observed between wild-type,
IMAGe-mutant and BWS-mutant CDKN1C in the G1
and S-phase cell distributions, we also examined levels
of cell cycle regulatory protein cyclin-A, a well estab-
lished S-phase marker [8]. Protein lysates from cells
transfected with IMAGe-mutant CDKN1C did not ex-
hibit accumulation of cyclin A as observed in cells trans-
fected with empty vector, wild-type, and BWS-mutant
CDKN1C (Figure 3B). This data shows that the loss of S-
phase transition occurs in cells transfected with IMAGe-
mutant CDKN1C, but not in empty vector, wild-type, or
BWS-mutant CDKN1C transfected cells. In accordance
with our results, Brioude et al., [6] found a higher percent-
age of cells in G1 phase in asynchronous cells transfected
with IMAGe-mutant. Collectively, these findings show
that the increased CDKN1C stability conferred by muta-
tions in the PCNA-binding domain mutations leads to im-
paired entry into S phase.
IMAGe-mutant CDKN1C decreases cell proliferation
To investigate the effects of CDKN1C protein stability on
cell proliferation we performed a clonogenic assay with the
wild-type, BWS-mutant and IMAGe-mutant CDKN1C in
HEK293T and SW13 cell lines. After transfection cell sus-
pensions were split into six-well plates. The cell cultures
were incubated for 7 days and the colonies were then
rinsed with PBS, fixed with methanol, and stained with
Crystal violet stain. Colonies with more than 50 cells were
counted. Assays were performed in triplicate.
All CDKN1C expressing plasmids caused a reduction
in the clonogenic capacity (fewer and smaller colonies)
when compared to the empty vector in both cell lines
(Figure 4A and B). IMAGe-mutant transfected cells
Figure 2 Synchronized cells transfected with IMAGe-mutant CDKN1C show loss of oscillation of CDKN1C through the cell cycle.
(A) Experimental outline for synchronization of HEK293T cells. Cells were synchronized with double thymidine block as on indicated. After the
first block cells were transfected with a empty, wild-type CDKN1C, BWS-mutant CDKN1C (p.L42P) or IMAGE-mutant CDKN1C (p.K278E) and then
synchronized again in early S phase with thymidine. After this process, a time was designated as “T0” and the cells were released and progressed
through the S-phase (B) Upon release, cells were collected at the indicated times and CDKN1C was analyzed by immunoblotting. Beta-actin was
used as a loading control. (C) Cell cycle analysis of double thymidine block synchronized cells transfected with empty plasmid, wild-type CDKN1C,
BWS-mutant (p.L42P) or IMAGE-mutant (p.K278E) CDKN1C.
Borges et al. Cell Division  (2015) 10:2 Page 3 of 6
Figure 3 IMAGe-mutants have decreased progression through S-phase after synchronization in S-phase. (A) Cell cycle analyses by flow
cytometry of cells at T0 transfected as described in Figure 2A. (B) Immunoblot analysis of transfected cells showed a failure of accumulation of
Cyclin-A, an S phase marker in IMAGe-mutant transfected cells at time T0.
Figure 4 Clonogenic assay of the HEK293T and SW13 cells transfected with IMAGe-mutant show decreased clonogenic capacity
compared to BWS or wild-type CDKN1C. After transfection of the wild-type CDKN1C, BWS-mutants (p.L42P), IMAGE-mutant (p.K278E) and an
empty vector, single cell suspensions were split into six-well in triplicate to assay for clonogenic capacity. (A) SW13 and (B) HEK293T cells results.
# indicates a p < 0.05 when compared to the empty-vector condition. *p = <0.05. (C) Representative dishes of SW13 cells transfected as described. Cells
were fixed and stained with Crystal violet solution; violet staining represents a higher number of colonies.
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displayed even fewer colonies than cells transfected
with wild-type CDKN1C in the two cell lines studied
(Figure 4A and B).
CDKN1C is a negative regulator of cell proliferation and
the effects observed on the wild-type transfected cells may
be attributed to a combination of the CDK-inhibitory and
PCNA domains of the CDKN1C. Moreover, the remaining
effects demonstrated by BWS-mutants probably are asso-
ciated with the intact PCNA-binding domain of CDKN1C,
as described previously [9]. In the IMAGe-mutant trans-
fected cells, the progression through the cell cycle is
impaired as cyclical degradation of CDKN1C is lost.
The G1-phase cell-cycle inhibition is increased due to in-
creased stability of CDKN1C IMAGe mutants, which
maintains an intact cyclin-dependent kinase binding do-
main, resulting in decreased proliferation and the under-
growth phenotype observed in patients with IMAGe
syndrome. Previous reports have described the in vitro
effects of variations in CDKN1C levels on cell growth
[10,11]. In vivo models have showed that mouse embry-
onic growth is sensitive to the precise dosage of Cdkn1c
and excess of this protein results in dose dependent em-
bryonic growth retardation [12], a phenotype seen in pa-
tients with IMAGe Syndrome.
Further expansion of the phenotypes associated with
mutations in CDKN1C’s PCNA binding domain suggests
phenotypic heterogeneity. Recently, mutations inducing
different missense changes of the arginine at amino acid
279 were found in individuals with IMAGe Syndrome
and Silver Russell Syndrome (SRS, MIM #180860), char-
acterized by prenatal and postnatal growth retardation
and dysmorphic features. We hypothesize that these dif-
ferences in amino acid changes (arginine to leucine in
SRS versus Arginine to Proline in IMAGe Syndrome)
are associated with a both differential loss of binding to
PCNA and the effects of modifier genes [6]. In addition
to SRS, missense mutations located in the highly con-
served PCNA binding domain have also been associated
with heterogeneous clinical phenotypes with growth
restriction and variable to no adrenal failure or skeletal
abnormalities and onset of diabetes in early adulthood
[13,14]. There the phenotypic spectrum associated with
missense mutations in the CDKN1C PCNA binding do-
main suggests the importance of genetic modifiers in dis-
ease manifestation.
Our data suggests that mutations in the PCNA-binding
domain of CDKN1C leads to increased protein stability, a
block in the G1 phase and impaired S-phase entry, and
decreased cell proliferation. Our findings demonstrate
that domain-specific mutations affect different aspects
of cell-cycle progression and cell proliferation, which
give rise to the two opposing phenotypes: BWS and
IMAGe syndrome. The data presented here give the
further direct evidence of how the PCNA-binding site
mutations in CDKN1C affect the cell cycle and cause
IMAGe syndrome.
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